Digestive Diseases and Sciences

, Volume 56, Issue 1, pp 109–114 | Cite as

CagA-Positive Helicobacter pylori Strains Enhanced Coronary Atherosclerosis by Increasing Serum OxLDL and HsCRP in Patients with Coronary Heart Disease

  • Bingsheng Huang
  • Ying Chen
  • Qiang Xie
  • Guixiong Lin
  • Yuyan Wu
  • Yanlin Feng
  • Jingcao Li
  • Yufeng Zhuo
  • Peng Zhang
Original Article



The role of infection in the pathogenesis of atherosclerosis is still a matter of debate.


This study aimed to investigate the effect of CagA-positive Helicobacter pylori (H. pylori) strains infection on coronary atherosclerosis in patients with coronary heart disease and to elucidate how cytotoxin-associated gene A (CagA)-positive H. pylori strains infections were involved in coronary heart disease by examining the levels of serum lipid, high-sensitivity C-reactive protein (hsCRP) and oxidized low-density protein (oxLDL).


Recruited for this study were 159 patients with coronary heart disease. The severity of coronary heart disease was estimated by calculating the Gensini score. Serum oxLDL and hsCRP were examined in all subjects. Current H. pylori infection was determined in all participants by means of a modified (13C) urea breath test (>200 dpm classified as positive). IgG antibodies against CagA protein were analyzed by enzyme immunoassays. Antibody titers against CagA (≥8 U/ml) were classified as positive. All subjects were divided into three groups, including an uninfected group (n = 30), an H. pylori+CagA group (n = 69), and an H. pylori+CagA+ group (n = 60).


Significant differences were found among the three groups in levels of total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, serum hsCRP, oxLDL, and severity of coronary atherosclerosis (p < 0.05). The levels of total cholesterol, LDL, apolipoprotein B, serum hsCRP, oxLDL were significantly elevated and the severity of coronary atherosclerosis was significantly increased in H. pylori+CagA+ group (p < 0.05).


More serious coronary atherosclerosis was observed in CHD patients with H. pylori+CagA+ infection. H. pylori+CagA+ infection might be involved in coronary atherosclerosis by modifying serum lipids, enhancing LDL oxidation, and activating the inflammatory responses.


Helicobacter pylori Coronary atherosclerosis Coronary heart disease Lipid C-reactive protein Oxidized low-density protein 


  1. 1.
    Sanders MK, Peura DA. Helicobacter pylori-associated diseases. Curr Gastroenterol Rep. 2002;4:448–454.CrossRefPubMedGoogle Scholar
  2. 2.
    Gasbarrini A, Franceschi F, Cammarota G, Pola P, Gasbarrini G. Vascular and immunological disorders associated with Helicobacter pylori infection. Ital J Gastroenterol Hepatol. 1998;30:115–118.PubMedGoogle Scholar
  3. 3.
    Gasbarrini A, De Luca A, Fiore G, et al. Beneficial effects of Helicobacter pylori eradication on migraine. Hepatogastroenterology. 1998;45:765–770.PubMedGoogle Scholar
  4. 4.
    Gasbarrini A, Serricchio M, Tondi P, et al. Raynaud’s phenomenon and Helicobacter pylori infection. Int J Angiol. 1998;7:307–309.CrossRefPubMedGoogle Scholar
  5. 5.
    Szklo M, Ding J, Tsai MY, et al. Individual pathogens, pathogen burden and markers of subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. J Cardiovasc Med. 2009;10:747–751.CrossRefGoogle Scholar
  6. 6.
    Kaklikkaya I, Kaklikkaya N, Buruk K, et al. Investigation of Chlamydia pneumoniae DNA, chlamydial lipopolisaccharide antigens, and Helicobacter pylori DNA in atherosclerotic plaques of patients with aortoiliac occlusive disease. Cardiovasc Pathol. 2006;15:105–109.CrossRefPubMedGoogle Scholar
  7. 7.
    Ozdogru I, Kalay N, Dogan A, et al. The relationship between Helicobacter pylori IgG titre and coronary atherosclerosis. Acta Cardiol. 2007;62:501–505.CrossRefPubMedGoogle Scholar
  8. 8.
    Chimienti G, Russo F, Lamanuzzi BL, et al. Helicobacter pylori is associated with modified lipid profile: impact on Lipoprotein(a). Clin Biochem. 2003;36:359–365.CrossRefPubMedGoogle Scholar
  9. 9.
    Niemelä S, Karttunen T, Korhonen T, et al. Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations? Heart. 1996;75:573–575.CrossRefPubMedGoogle Scholar
  10. 10.
    Hoffmeister A, Rothenbacher D, Bode G, et al. Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or Cytomegalovirus, is associated with an atherogenic, modified lipid profile. Arterioscler Thromb VascBiol. 2001;21:427–432.Google Scholar
  11. 11.
    Crabtree JE, Shallcross TM, Heatley RV. Mucosal tumour necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori associated gastritis. Gut. 1991;32(10):1473–1477.CrossRefPubMedGoogle Scholar
  12. 12.
    Zito F, Di Castelnuovo A. Helicobacter pylori infection and the risk of myocardial infarction, role of fibrinogen and its genetic control. Thromb Haemost. 1999;82(1):14–18.PubMedGoogle Scholar
  13. 13.
    Kayo S, Ohsawa M, Ehara S, et al. Oxidized low-density lipoprotein levels circulating in plasma and deposited in the tissues: comparison between Helicobacter pylori-associated gastritis and acute myocardial infarction. Am Heart J. 2004;148:818–825.CrossRefPubMedGoogle Scholar
  14. 14.
    Mayr M, Kiechl S, Tsimikas S, et al. Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study. J Am Coll Cardiol. 2006;47:2436–2443.CrossRefPubMedGoogle Scholar
  15. 15.
    Mayr M, Kiechl S, Willeit J, Wick G, Xu Q. Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and Cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation. 2000;102:833–839.PubMedGoogle Scholar
  16. 16.
    Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51:606.CrossRefPubMedGoogle Scholar
  17. 17.
    Itabe H, Yamamoto H, Imanaka T, et al. Sensitive detection of oxidatively modified low-density lipoprotein using a monoclonal antibody. J Lipid Res. 1996;37:45–53.PubMedGoogle Scholar
  18. 18.
    Adiloglu AK, Ocal A, Can R, Duver H, Yavuz T, Aridogan BC. Detection of Helicobacter pylori and Chlamydia pneumoniae DNA in human coronary arteries and evaluation of the results with serologic evidence of inflammation. Saudi Med J. 2005;26:1068–1074.PubMedGoogle Scholar
  19. 19.
    Kowalski M, Pawlik M, Konturek JW, Konturek SJ. Helicobacter pylori infection in coronary artery disease. J Physiol Pharmol. 2006;57:101–111.Google Scholar
  20. 20.
    Niu YH, Xu CF, Shi JH, Ge JB. Relationship between infection burden and atherosclerosis and plaque feature. Zhonghua Xin Xue Guan Bing Za Zhi. 2005;33:303–306.PubMedGoogle Scholar
  21. 21.
    Michael R, Armin J, Buggle F, et al. Association between cerebral ischemia and cytotoxin-associated gene-a-bearing strains of Helicobacter pylori. Stroke. 2004;35:1800.CrossRefGoogle Scholar
  22. 22.
    Zhang S, Guo Y, Ma Y, Teng Y. Cytotoxin-associated gene-A-seropositive virulent strains of Helicobacter pylori and atherosclerotic diseases: a systematic review. Chin Med J. 2008;121:946–951.PubMedGoogle Scholar
  23. 23.
    Mayr M, Kiechl S, Mendall MA, Willeit J, Wick G, Xu QB. Increased risk of atherosclerosis is confined to CagA-positive Helicobacter pylori strains prospective results from the Bruneck study. Stroke. 2003;34:610–615.CrossRefPubMedGoogle Scholar
  24. 24.
    Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997;350:430–436.CrossRefPubMedGoogle Scholar
  25. 25.
    Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation. 1997;96:4095–4103.PubMedGoogle Scholar
  26. 26.
    Mehta JL, Saldeen TGP, Rand K. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol. 1998;31:1217–1225.CrossRefPubMedGoogle Scholar
  27. 27.
    Covacci A, Censini S, Bugnoli M, et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci USA. 1993;90:5791–5795.CrossRefPubMedGoogle Scholar
  28. 28.
    Oshima T, Ozono R, Yano Y, et al. Association of Helicobacter pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjects. Am Coll Cardiol. 2005;45:1219–1222.CrossRefGoogle Scholar
  29. 29.
    Saijo Y, Utsugi M, Yoshioka E, et al. Relationship of Helicobacter pylori infection to arterial stiffness in Japanese subjects. Hypertens Res. 2005;28:283–292.CrossRefPubMedGoogle Scholar
  30. 30.
    Diomedi M, Pietroiusti A, Silvestrini M, et al. CagA positive Helicobacter pylori strains may influence the natural history of atherosclerotic stroke. Neurology. 2004;63:800–804.PubMedGoogle Scholar
  31. 31.
    Kiechl S, Egger G, Mayr M, et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation. 2001;103:1064–1070.PubMedGoogle Scholar
  32. 32.
    Zhu J, Quyyumi AA, Norman JE, Csako G, Epstein SE. Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive protein levels. J Am Coll Cardiol. 1999;34:1738–1743.CrossRefPubMedGoogle Scholar
  33. 33.
    Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89:763–771.CrossRefPubMedGoogle Scholar
  34. 34.
    Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 2002;347:185–192.CrossRefPubMedGoogle Scholar
  35. 35.
    Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915–924.CrossRefPubMedGoogle Scholar
  36. 36.
    Steinberg D, Witztum JL. Lipoproteins and atherogenesis: current concepts. JAMA. 1990;264:3047–3052.CrossRefPubMedGoogle Scholar
  37. 37.
    Steinberg D. Low-density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997;272:20963–20966.CrossRefPubMedGoogle Scholar
  38. 38.
    Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low-density lipoprotein. Proc Natl Acad Sci USA. 1995;92:3893–3897.CrossRefPubMedGoogle Scholar
  39. 39.
    Smith C, Mitchinson MJ, Aruoma OI, Halliwell B. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J. 1992;286:901–905.PubMedGoogle Scholar
  40. 40.
    Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with severity of acute coronary syndromes. Circulation. 2001;103:1955–1960.PubMedGoogle Scholar
  41. 41.
    Naruko T, Ueda M, Haze K, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 2002;106:2894–2900.CrossRefPubMedGoogle Scholar
  42. 42.
    Azumi H, Inoue N, Ohashi Y, et al. Superoxide generation in directional coronary atherectomy specimens of patients with angina pectoris: important role of NAD(P)H oxidase. Arterioscler Thromb Vasc Biol. 2002;22:1838–1844.CrossRefPubMedGoogle Scholar
  43. 43.
    Huang B, Dong Y, Mai W, Li Y. Effect of Chlamydia pneumoniae infection and hyperlipidaemia on the expression of PPARgamma, P50 and c-Fos in aortic endothelial cells in C57bL/6 J mice. Acta Cardiol. 2005;60(1):43–49.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Bingsheng Huang
    • 1
    • 2
  • Ying Chen
    • 1
  • Qiang Xie
    • 1
  • Guixiong Lin
    • 1
  • Yuyan Wu
    • 1
  • Yanlin Feng
    • 1
  • Jingcao Li
    • 1
  • Yufeng Zhuo
    • 1
  • Peng Zhang
    • 1
  1. 1.Department of CardiologyThe He Xian Memorial Hospital of Panyu DistrictGuangzhouPeople’s Republic of China
  2. 2.Guangzhou CityPeople’s Republic of China

Personalised recommendations